Long Term Incidence of Secondary Malignancies Following Allogeneic Hematopoietic Cell Transplantation: a Single Center Experience.
Biol Blood Marrow Transplant. 2017 Feb 27;:
Improved prognostic stratification power of CIBMTR risk score with the addition of absolute lymphocyte and eosinophil counts at the onset of chronic GVHD.
Ann Hematol. 2017 Feb 18;:
Brentuximab vedotin and bendamustine produce high complete response rates in patients with chemotherapy refractory Hodgkin lymphoma.
Br J Haematol. 2016 Dec 16;:
Gamma Delta T Cell Subset V Gamma 2+ Expansion Associated with Longterm Infliximab Treatment in a Patient with Ankylosing Spondylitis.
J Rheumatol. 2016 Nov;43(11):2079-2082
The CDK inhibitor AT7519M in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. A Phase II study of the Canadian Cancer Trials Group.
Leuk Lymphoma. 2016 Oct 17;:1-8
Myeloablative Versus Reduced-Intensity Conditioning in Patients with Myeloid Malignancies: a Propensity Score Matched Analysis.
Biol Blood Marrow Transplant. 2016 Sep 2;
Curr Oncol. 2016 Aug;23(4):e409-30
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.
Lancet Oncol. 2016 Jul 20;
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
J Clin Oncol. 2016 Jun 27;